Supernus Pharmaceuticals Pre-Tax Income 2011-2024 | SUPN
Supernus Pharmaceuticals pre-tax income from 2011 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Supernus Pharmaceuticals Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$3 |
| 2022 |
$61 |
| 2021 |
$73 |
| 2020 |
$169 |
| 2019 |
$147 |
| 2018 |
$140 |
| 2017 |
$101 |
| 2016 |
$50 |
| 2015 |
$15 |
| 2014 |
$-10 |
| 2013 |
$-92 |
| 2012 |
$-46 |
| 2011 |
$-39 |
| 2010 |
$-39 |
Supernus Pharmaceuticals Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-09-30 |
$45 |
| 2024-06-30 |
$26 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$10 |
| 2023-06-30 |
$-17 |
| 2023-03-31 |
$9 |
| 2022-12-31 |
$35 |
| 2022-09-30 |
$-0 |
| 2022-06-30 |
$11 |
| 2022-03-31 |
$15 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$29 |
| 2021-06-30 |
$31 |
| 2021-03-31 |
$11 |
| 2020-12-31 |
$40 |
| 2020-09-30 |
$53 |
| 2020-06-30 |
$47 |
| 2020-03-31 |
$29 |
| 2019-12-31 |
$41 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
$43 |
| 2019-03-31 |
$24 |
| 2018-12-31 |
$39 |
| 2018-09-30 |
$36 |
| 2018-06-30 |
$34 |
| 2018-03-31 |
$31 |
| 2017-12-31 |
$35 |
| 2017-09-30 |
$23 |
| 2017-06-30 |
$26 |
| 2017-03-31 |
$16 |
| 2016-12-31 |
$16 |
| 2016-09-30 |
$19 |
| 2016-06-30 |
$11 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$-24 |
| 2013-06-30 |
$-27 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-14 |
| 2012-09-30 |
$-13 |
| 2012-06-30 |
$-10 |
| 2012-03-31 |
$-9 |
| 2011-12-31 |
$-11 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-9 |
| 2011-03-31 |
$-10 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
